Bavarian Nordic afholder telefonkonference i forbindelse med offentliggørelse af årsregnskabet for 2018
March 18, 2019 12:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KØBENHAVN, 18. marts 2019 - Bavarian Nordic...
Bavarian Nordic Announces FDA Delay in the Review of the Biologics License Application for MVA-BN Smallpox Vaccine
March 11, 2019 14:39 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark, March 11, 2019 -...
Bavarian Nordic meddeler en forsinkelse af de amerikanske sundhedsmyndigheders behandling af registreringsansøgningen for MVA-BN® koppevaccine
March 11, 2019 14:39 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KØBENHAVN, Danmark, 11. marts 2019 - Bavarian...
Bavarian Nordic offentliggør påbegyndelsen af fase 1/2a klinisk forsøg med terapeutisk HPV vaccine i samarbejde med Janssen
February 21, 2019 13:33 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Første kommercielle program i samarbejdet...
Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen
February 21, 2019 13:33 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
First commercial program under...
Bavarian Nordic fuldfører rekruttering til første del af fase 2 forsøg i chordoma-kræft
January 25, 2019 05:58 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KØBENHAVN, Danmark, 25. januar 2019 - Bavarian...
Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial
January 25, 2019 05:58 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark, January 25, 2019 -...
Bavarian Nordic fortsætter udviklingen af vaccine mod hesteencephalit virus
January 24, 2019 01:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
KØBENHAVN, Danmark, 24. januar 2019 - Bavarian...
Bavarian Nordic Advances Development of Equine Encephalitis Virus Vaccine
January 24, 2019 01:30 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark, January 24, 2019 -...
Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine
January 18, 2019 01:14 ET
|
Bavarian Nordic A/S
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
COPENHAGEN, Denmark, January 18, 2019...